
Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer

Supplementary Materials



Supplementary Figure 1: Ki67 Immunostaining of GBC xenografts. Ki67 proliferation index was assessed by immunohistochemistry in G-415 xenografts collected 34 days after starting the treatment. Ki67 positive cells were counted to calculate the Ki67 proliferation index. Data are expressed as mean \pm SD. (ns: not significant).

Supplementary Table 1: List of drugs and IC50 (nM). See Supplementary Table 1

| Cell line | <i>In vitro</i> Invasion Phenotype | Case history | Tissue derived from | Gender | Age | Differentiation |
|--------------|---------------------------------------|----------------|-------------------------|--------|-----|------------------|
| GB-D1 | High | Adenocarcinoma | Gallbladder | М | 58 | Poor |
| G-415 | High | Carcinoma | Gallbladder | М | 68 | Undifferentiated |
| SNU308 | Less | Adenocarcinoma | Gallbladder | NA | NA | Moderate |
| NOZ | Moderate | Adenocarcinoma | Gallbladder | F | 48 | Moderate |
| TGBC1TKB (M) | Less | Carcinoma | Gallbladder, lymph node | F | NA | NA |
| TGBC2TKB (P) | Less | Carcinoma | Gallbladder | F | NA | NA |
| TGBC24TKB | Non invasive | Carcinoma | Gallbladder, ascites | F | NA | NA |

Supplementary Table 2: Gallbladder cancer cell lines used in the rapid small molecule inhibitors